365 Days of Progress In Cancer Genetics

10K

views

33

authors

5

articles

365 Days of Progress In Cancer Genetics

10K

views

33

authors

5

articles

Editorial

26 September 2023

Editorial: 365 days of progress in cancer genetics

Magdalena Ratajska

,

Claudio Sette

and

Heather E. Cunliffe

864 views

0 citations

Editors

2

Heather Cunliffe

University of Otago

Department of Neuroscience, Catholic University of the Sacred Heart, Rome

Impact

About

“365 Days of Progress” is part of a wider series of Research Topics across Frontiers in Oncology, hosted by our Specialty Chief Editors, showcasing popular articles from 2021 igniting interest in the field.

This Research Topic aims to highlight the work featured and spark further discussion. The Cancer Genetics field is continuously evolving, therefore we are seeking to understand developments and perspectives on articles that have attracted attention throughout the year.

We welcome Opinions, Perspectives, and Mini-Review article types to facilitate this discussion. We also welcome updated original data following the research featured in this collection. Please note only papers that are relevant and add a significant contribution to the discussion articles will be considered.

The chosen manuscripts are :

- FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

- Somatic Copy Number Alterations in Human Cancers: An Analysis of Publicly Available Data From The Cancer Genome Atlas

- The Detection of Cancer Epigenetic Traces in Cell-Free DNA

- Single-Cell Transcriptomics Reveals the Complexity of the Tumor Microenvironment of Treatment-Naive Osteosarcoma

- Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives

- Regulation of Gene Expression Associated With the N6-Methyladenosine (m6A) Enzyme System and Its Significance in Cancer

- LncRNA-Encoded Peptide: Functions and Predicting Methods

- The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy

Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

“365 Days of Progress” is part of a wider series of Research Topics across Frontiers in Oncology, hosted by our Specialty Chief Editors, showcasing popular articles from 2021 igniting interest in the field.

This Research Topic aims to highlight the work featured and spark further discussion. The Cancer Genetics field is continuously evolving, therefore we are seeking to understand developments and perspectives on articles that have attracted attention throughout the year.

We welcome Opinions, Perspectives, and Mini-Review article types to facilitate this discussion. We also welcome updated original data following the research featured in this collection. Please note only papers that are relevant and add a significant contribution to the discussion articles will be considered.

The chosen manuscripts are :

- FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

- Somatic Copy Number Alterations in Human Cancers: An Analysis of Publicly Available Data From The Cancer Genome Atlas

- The Detection of Cancer Epigenetic Traces in Cell-Free DNA

- Single-Cell Transcriptomics Reveals the Complexity of the Tumor Microenvironment of Treatment-Naive Osteosarcoma

- Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives

- Regulation of Gene Expression Associated With the N6-Methyladenosine (m6A) Enzyme System and Its Significance in Cancer

- LncRNA-Encoded Peptide: Functions and Predicting Methods

- The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy

Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

Share

Editors

Heather Cunliffe

University of Otago

Department of Neuroscience, Catholic University of the Sacred Heart, Rome

Impact

9,957 Total views

5,947 Article views

3,744 Article downloads

266 Topic views

Published In

Journal Thumbnail

Frontiers in Oncology

Cancer Genetics

Journal Thumbnail

Frontiers in Genetics

Cancer Genetics

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic